Hepatitis B and human immunodeficiency virus coinfection

Hepatology

Volumn 49, Issue SUPPL. 5, 2009, Pages

  Thio, Chloe L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; VIRUS DNA; ANTIVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MIXED INFECTION; MORBIDITY; MORTALITY; NONHUMAN; OPPORTUNISTIC INFECTION; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE; COMORBIDITY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ANTIVIRAL AGENTS; COMORBIDITY; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 66149187114     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.22883     Document Type: Article

References (46)

1. McGovern BH. The epidemiology, natural history and prevention of hepatitis B: implications of HIV co-infection. Antivir Ther 2007; 12(Suppl 3): H3-H13.
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44(1 Suppl ): S6-S9.
3. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
4. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121-130.
5. Chapman LE, Sullivent EE, Grohskopf LA, Beltrami EM, Perz JF, Kretsinger K, et al. Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events-United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 2008; 57 (RR-6): 1-21.
6. Lee HC, Ko NY, Lee NY, Chang CM, Ko WC. Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection in Southern Taiwan, 2000-2005: upsurge in hepatitis C virus infections among injection drug users. J Formos Med Assoc 2008; 107: 404-411.
7. Nyirenda M, Beadsworth MB, Stephany P, Hart CA, Hart IJ, Munthali C, et al. Prevalence of infection with hepatitis B and C virus and co-infection with HIV in medical inpatients in Malawi. J Infect 2008; 57: 72-77.
8. Diop-Ndiaye H, Toure-Kane C, Etard JF, Lo G, Diaw P, Ngom-Gueye NF, et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol 2008; 80: 1332-1336.
9. Harania RS, Karuru J, Nelson M, Stebbing J. HIV, hepatitis B and hepatitis C co-infection in Kenya. AIDS 2008; 22: 1221-1222.
10. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B carrier state. J Infect Dis 1991; 163: 1138-1140.
11. Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, Buchbinder S, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991; 163: 454-459.
12. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. HEPATOLOGY 1999; 29: 1306-1310.
13. Gilson RJ, Hawkins AE, Beecham MR, Ross E, Waite J, Briggs M, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS 1997; 11: 597-606.
14. Krogsgaard K, Lindhardt BO, Nielsen JO, Andersson P, Kryger P, Aldershvile J, et al. The influence of HTLV-III infection on the natural history of hepatitis B virus infection in males homosexual carriers. HEPATOLOGY 1987; 7: 37-41.
15. Biggar RJ, Goedert JJ, Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodificient homosexual men infected with HIV. N Engl J Med 1987; 316: 630.
16. Laukamm-Josten U, Muller O, Bienzle U, Feldmeier H, Uy A, Guggenmoos-Holzmann I. Decline of naturally acquired antibodies to hepatitis B surface antigen in HIV-1 infected homosexual men. AIDS 1988; 2: 400-401.
17. Di Martino V, Thevenot T, Colin JF, Boyer N, Martinot M, Degos F, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123: 1812-1822.
18. Thio CL, Seaberg EC, Skolasky RL, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
19. Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008; 22: 2135-2141.
20. Fang JW, Wright TL, Lau JY. Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet 1993; 342: 1175.
21. Revill PA, Littlejohn M, Ayres A, Yuen L, Colledge D, Bartholomeusz A, et al. Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. AIDS 2007; 21: 1701-1710.
22. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. HEPATOLOGY 2008; 48: 88-98.
23. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.
24. Mathurin P, Deng QG, Keshavarzian A, Choudhary S, Holmes EW, Tsukamoto H. Exacerbation of alcoholic liver injury by enteral endotoxin in rats. HEPATOLOGY 2000; 32: 1008-1017.
25. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135: 226-233.
26. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2008: 1-128.
27. Hofer M, Joller-Jemelka HI, Grob PJ, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998; 17: 6-13.
28. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 36: 869-875.
29. Gandhi RT, Wurcel A, McGovern B, Lee H, Shopis J, Corcoran CP, et al. Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen. J Acquir Immune Defic Syndr 2003; 34: 439-441.
30. Gandhi RT, Wurcel A, Lee H, McGovern B, Shopis J, Geary M, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005; 191: 1435-1441.
31. Sheng WH, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, et al. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 45: 1221-1229.
32. Marcellin P, Ziol M, Bedossa P, Douvin C, Poupon R, de Lédinghen V, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2008; doi:10.1111/j.1478-3231.2008.01802.x.
33. Chang PE, Lui HF, Chau YP, Lim KH, Yap WM, Tan CK, et al. Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate transaminase platelet ratio index. Aliment Pharmacol Ther 2008; 28: 51-61.
34. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-180.
35. Benhamou Y, Bochet M, Thibault V, Calvez V, Fievet MH, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-723.
36. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 Update. Clin Gastroenterol Hepatol 2008; 6: 1315-1341.
37. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. HEPATOLOGY 2008; 48: 1062-1069.
38. Matthews GV, Seaberg EC, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, et al. Combination of HBV-active antiretroviral therapy influences HBV virological suppression in an international cohort of 120 HIV-HBV co-infected individuals. In: 42nd European Association for the Study of the Liver; April 11-15, 2007; Barcelona, Spain.
39. McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med 2007; 356: 2614-2621.
40. Baraclude Package Insert. Bristol-Myers Squibb Co., Princeton, NJ; 2005.
41. Pessoa MG, Gazzard B, Huang AK, Brandao-Mello CE, Cassetti I, Mendes-Correa MC, et al. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. AIDS 2008; 22: 1779-1787.
42. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20: 863-870.
43. Johnson RM, Ristig MB, Overton ET, Lisker-Melman M, Cummings OW, Aberg JA. Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals. HIV Clin Trials 2007; 8: 173-181.
44. Bellini C, Keiser O, Chave JP, Evison J, Fehr J, Kaiser L, et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med 2009; 10: 12-18.
45. Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B co-infection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004; 39: 129-132.
46. Lascar RM, Gilson RJ, Lopes AR, Bertoletti A, Maini MK. Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV co-infection. J Infect Dis 2003; 188: 1815-1819.